Zepbound and Apixaban Interaction: What Patients and Prescribers Need to Know

What the Zepbound label says about oral medicines

Zepbound is a once-weekly subcutaneous tirzepatide injection, approved for weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity [1]. Its drug interactions section states that tirzepatide delays gastric emptying and therefore has the potential to affect the absorption of oral medicines given at the same time, and that caution should be used when oral medications are given with it [1]. The label asks prescribers to monitor oral drugs that depend on threshold concentrations for efficacy and those with a narrow therapeutic index, naming warfarin as its example [1]. Apixaban is not named in that section.

The same section gives one specific instruction tied to that mechanism. The label advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation, and says use may reduce their efficacy because of delayed gastric emptying [1].

The label's own absorption data used acetaminophen. After a first 5 mg dose of tirzepatide, acetaminophen peak concentration fell 55% and the time to peak was about 1 hour later. By week 6 on 15 mg weekly there was no meaningful effect on acetaminophen peak concentration or time to peak, and total exposure (AUC) was not changed [1]. The label says the delay in gastric emptying is largest after the first dose and diminishes over time [1].

How apixaban is handled in the body

Apixaban is an oral direct factor Xa inhibitor, first approved in December 2012 [4]. Peak plasma concentration occurs about 3 to 4 hours after a dose, absolute bioavailability is about 50%, food has no clinically meaningful effect on it, and the half-life is about 12 hours [2]. About 27% of total clearance is renal [2]. It is given as a fixed dose without routine coagulation monitoring [2].

Apixaban exposure shifts substantially when other drugs act on its clearance pathways. In 18 healthy subjects, ketoconazole 400 mg daily raised apixaban AUC by 99% and peak concentration by 62%, and diltiazem 360 mg daily raised AUC by 40% and peak concentration by 31% [5]. In 20 healthy participants, rifampin 600 mg daily cut oral apixaban AUC by 54% and lowered oral bioavailability from 49% to 39% [6].

Does tirzepatide act on that pathway?

The Zepbound label reports that tirzepatide is broken down by proteolytic cleavage of its peptide backbone, beta-oxidation of its fatty diacid and amide hydrolysis rather than by CYP enzymes, and that it has low in vitro potential to inhibit or induce CYP enzymes [1]. The only route the label describes for tirzepatide affecting another oral drug is slower gastric emptying [1].

Apixaban's bleeding and stroke rates in ARISTOTLE

In ARISTOTLE, 18,201 people with atrial fibrillation received apixaban 5 mg twice daily or warfarin. Major bleeding occurred at 2.13% per year on apixaban versus 3.09% per year on warfarin (HR 0.69, 95% CI 0.60-0.80), and stroke or systemic embolism at 1.27% versus 1.60% per year (HR 0.79, 95% CI 0.66-0.95) [3].

Weight loss and apixaban dosing

For atrial fibrillation, the Eliquis label sets 5 mg twice daily, with 2.5 mg twice daily if the patient has at least 2 of 3 features: age 80 or older, body weight 60 kg or less, and serum creatinine 1.5 mg/dL or more.

Tirzepatide produces large weight change. In SURMOUNT-1, 2,539 adults with obesity or overweight but no diabetes lost a mean 20.9% of body weight on 15 mg weekly versus 3.1% on placebo at 72 weeks, from a mean baseline weight of 104.8 kg [8]. A person starting near 60 kg could fall below that mark. Body weight of 60 kg or less is only one of the three Eliquis criteria, and the label's rule requires at least two of them.

Nausea, vomiting and kidney function

At 15 mg weekly in the pooled Zepbound weight trials, nausea occurred in 28% versus 8% on placebo, diarrhea in 23% versus 8%, and vomiting in 13% versus 2%. Any gastrointestinal adverse reaction occurred in 56% of tirzepatide-treated patients versus 30% on placebo, and most nausea, vomiting and diarrhea happened during dose escalation and decreased over time [1].

The Zepbound label warns about acute kidney injury from volume depletion, with postmarketing reports mostly in patients who had nausea, vomiting or diarrhea. It asks prescribers to monitor renal function in patients reporting reactions that could cause volume depletion, especially during starting and dose increases [1].